Drug profile · INN
lumasiran sodium
OXLUMO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
lumasiran sodium (OXLUMO) is an FDA-listed pharmaceutical active ingredient. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN lumasiran sodium
Brand OXLUMO
Route SUBCUTANEOUS
Formulation SOLUTION
Originator Alnylam Netherlands B.V.
Frequently asked questions
What is lumasiran sodium?
lumasiran sodium (OXLUMO) is an FDA-listed pharmaceutical active ingredient. Associated with Alnylam Netherlands B.V.. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lumasiran sodium?
OXLUMO is a marketed brand name for lumasiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lumasiran sodium?
lumasiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.